

# Michael S Niederman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7320939/michael-s-niederman-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

8,110  
citations

33  
h-index

90  
g-index

130  
ext. papers

9,785  
ext. citations

8.8  
avg, IF

6.17  
L-index

#	Paper	IF	Citations
93	Aspiration pneumonia.. <i>Revista Espanola De Quimioterapia</i> , <b>2022</b> , 35 Suppl 1, 73-77	1.6	0
92	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , <b>2021</b> ,	25.5	0
91	How low can we go in community-acquired pneumonia therapy?. <i>Lancet</i> , <b>2021</b> , 397, 1160-1161	40	1
90	Pneumonia. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 25	51.1	31
89	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 807-814	4.7	0
88	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1087-1097	4.7	3
87	Updates on community acquired pneumonia management in the ICU. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 217, 107663	13.9	12
86	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , <b>2021</b> , 20, 243-256	5.2	10
85	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , <b>2021</b> , 20, 257-267	5.2	3
84	Initial antimicrobial management of sepsis. <i>Critical Care</i> , <b>2021</b> , 25, 307	10.8	14
83	Management of pneumonia in critically ill patients. <i>BMJ</i> , <b>2021</b> , 375, e065871	5.9	3
82	Antibiotic Stewardship in the Intensive Care Unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 531-540	4.7	24
81	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. <i>Chest</i> , <b>2020</b> , 158, 1008-1016	5.3	8
80	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , <b>2020</b> , 158, 1896-1911	5.3	20
79	Letter from the United States: A New York experience with COVID-19. <i>Respirology</i> , <b>2020</b> , 25, 900-902	3.6	2
78	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 330-340	25.5	38
77	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , <b>2020</b> , 29,	9.8	50

76	The INHALE trial: multiple reasons for a negative result - AuthorsReply. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 779-780	25.5	1
75	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
74	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , <b>2019</b> , 45, 159-171	14.5	49
73	Update in Lung Infections and Tuberculosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 414-422	10.2	0
72	Adjunctive Nebulized Antibiotics: What Is Their Place in ICU Infections?. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 99	4.9	8
71	24th International Symposium on Infections in the Critically Ill Patient. <i>Medical Sciences (Basel, Switzerland)</i> , <b>2019</b> , 7,	3.3	1
70	A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1080-1088	11.6	15
69	Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 445-452	6.2	1
68	Aspiration Pneumonia. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 651-663	59.2	183
67	Effect of Combined $\beta$ -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , <b>2019</b> , 155, 795-804	5.3	18
66	Future Research Directions in Pneumonia. NHLBI Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 256-263	10.2	33
65	Antibiotic treatment of hospital-acquired pneumonia: is it different from ventilator-associated pneumonia?. <i>Current Opinion in Critical Care</i> , <b>2018</b> , 24, 353-360	3.5	10
64	Pneumonia Complicating COPD: Are Corticosteroids a Help or a Hindrance?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2018</b> , 5, 1-4	2.7	0
63	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , <b>2018</b> , 4,	3.5	23
62	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , <b>2017</b> , 151, 1311-1319	5.3	12
61	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , <b>2017</b> , 43, 1389-1391	14.5	5
60	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , <b>2017</b> , 43, 1572-1584	14.5	20
59	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci3n Latinoamericana del T3ax (ALAT). <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	425

58	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178022	3.7	9
57	Using Ventilator-Associated Pneumonia Rates as a Health Care Quality Indicator: A Contentious Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 237-244	3.9	4
56	Serum procalcitonin and the admission decision in CAP. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 956	35.1	1
55	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , <b>2016</b> , 42, 1374-86	14.5	48
54	Outcomes and Prognostic Features of Patients With Influenza Requiring Hospitalization and Receiving Early Antiviral Therapy: A Prospective Multicenter Cohort Study. <i>Chest</i> , <b>2016</b> , 149, 526-534	5.3	30
53	New Strategies to Prevent Ventilator-Associated Pneumonia: What to Do for Your Patients. <i>Current Treatment Options in Infectious Diseases</i> , <b>2016</b> , 8, 1-15	1	1
52	Bacteraemia in outpatients with community-acquired pneumonia. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 654-7	13.6	6
51	Lessons learned from 2 decades of CAP therapy data: ways to improve patient management. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E455-9	2.6	1
50	The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 1519-26	4.7	41
49	Principles of Antibiotic Management of Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2016</b> , 37, 905-912	3.9	4
48	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , <b>2016</b> , 150, 415-25	5.3	66
47	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 257-61	13.6	7
46	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 677-86	27.4	306
45	Ventilator-associated pneumonia prevention: response to Silvestri et al. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 957	14.5	
44	Ventilator-associated pneumonia: present understanding and ongoing debates. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 34-48	14.5	104
43	Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 112	3.5	5
42	Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Nosocomial Pneumonia (NP). <i>PLoS ONE</i> , <b>2015</b> , 10, e0131932	3.7	7
41	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1353-63	13.6	33

40	Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i> : secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1233-1243.e1	3.5	20
39	Reply to Yamamoto et al. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1040-1	11.6	
38	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. <i>Intensive Care Medicine</i> , <b>2013</b> , 39, 672-81	14.5	95
37	Acute lower respiratory infections in developing countries. <i>Lancet, The</i> , <b>2013</b> , 381, 1341-1342	40	14
36	A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 1373-83	11.6	87
35	Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia?. <i>Chest</i> , <b>2013</b> , 144, 63-71	5.3	44
34	BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. <i>Intensive Care Medicine</i> , <b>2012</b> , 38, 263-71	14.5	131
33	Linezolid in methicillin-resistant <i>Staphylococcus aureus</i> nosocomial pneumonia: a randomized, controlled study. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 621-9	11.6	414
32	Community-acquired pneumonia guidelines: a global perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2012</b> , 33, 298-310	3.9	35
31	Pneumonia complicating pregnancy. <i>Clinics in Chest Medicine</i> , <b>2011</b> , 32, 121-132	5.3	34
30	De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia?. <i>Clinics in Chest Medicine</i> , <b>2011</b> , 32, 517-34	5.3	34
29	Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51 Suppl 1, S12-7	11.6	57
28	Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new Speed limit?. <i>Thorax</i> , <b>2010</b> , 65, 944-5	7.3	10
27	The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51 Suppl 1, S93-9	11.6	31
26	Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. <i>BMJ, The</i> , <b>2010</b> , 340, c1004	5.9	173
25	The delivery of futile care is harmful to other patients. <i>Critical Care Medicine</i> , <b>2010</b> , 38, S518-22	1.4	51
24	Community-acquired pneumonia: the U.S. perspective. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2009</b> , 30, 179-88	3.9	37
23	Treatment options for nosocomial pneumonia due to MRSA. <i>Journal of Infection</i> , <b>2009</b> , 59 Suppl 1, S25-31.9	18.9	16

22	Making sense of scoring systems in community acquired pneumonia. <i>Respirology</i> , <b>2009</b> , 14, 327-35	3.6	41
21	Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. <i>Current Opinion in Infectious Diseases</i> , <b>2009</b> , 22, 316-25	5.4	118
20	Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47 Suppl 3, S127-32	11.6	52
19	Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. <i>Infection Control and Hospital Epidemiology</i> , <b>2007</b> , 28, 825-31	2	112
18	Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44 Suppl 2, S27-72	11.6	4193
17	Recent advances in community-acquired pneumonia: inpatient and outpatient. <i>Chest</i> , <b>2007</b> , 131, 1205-15;3	5.3	57
16	Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. <i>Chest</i> , <b>2007</b> , 131, 779-787	5.3	78
15	The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2006</b> , 27, 45-50	3.9	26
14	Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42 Suppl 2, S72-81	11.6	98
13	De-escalation therapy in ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , <b>2006</b> , 12, 452-7;5	3.5	46
12	Principles of appropriate antibiotic use. <i>International Journal of Antimicrobial Agents</i> , <b>2005</b> , 26 Suppl 3, S170-5	14.3	48
11	Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41 Suppl 2, S158-66	11.6	11
10	The clinical diagnosis of ventilator-associated pneumonia. <i>Respiratory Care</i> , <b>2005</b> , 50, 788-96; discussion 807-12	2.1	27
9	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 749-56	2.5	12
8	Review of treatment guidelines for community-acquired pneumonia. <i>The American Journal of Medicine: Supplement</i> , <b>2004</b> , 117 Suppl 3A, 51S-57S		18
7	Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 969-80	2.5	9
6	Appropriate use of antimicrobial agents: challenges and strategies for improvement. <i>Critical Care Medicine</i> , <b>2003</b> , 31, 608-16	1.4	72
5	Community-acquired pneumonia. <i>Israel Medical Association Journal</i> , <b>2003</b> , 5, 133-8	0.9	

- |   |  |     |    |
|---|--|-----|----|
| 4 | Can optimal management prevent mortality in ventilator-associated pneumonia?. <i>Critical Care Medicine</i> , <b>2002</b> , 30, 1916-7   | 1.4 | 10 |
| 3 | Respiratory Infection in the Critically Ill: Mechanisms and the Role of Apoptosis in the Response to Infection. <i>Sepsis</i> , <b>1998</b> , 1, 153-159   |     |    |
| 2 | Characterization of <i>Pseudomonas aeruginosa</i> adherence to cultured hamster tracheal epithelial cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1991</b> , 5, 563-70 | 5.7 | 17 |
| 1 | β-Lactams in the Therapy of Community-Acquired Pneumonia153-169  |     |    |